Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.37 |
| ▸ | ELANE | P08246 | 3/20 | 0.36 |
| ▸ | MMP2 | P08253 | 3/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | BCL2 | P10415 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19650261 | 0.86 | ELANE (0.45) | MCL1ELANE | |
| SCHEMBL10221208 | 0.86 | ELANE (0.45) | MCL1ELANE | |
| SCHEMBL15258576 | 0.86 | ELANE (0.45) | MCL1ELANE | |
| SCHEMBL13757878 | 0.85 | AAK1 (0.46) | AAK1CACNA1BMCL1MMP2MMP9 | |
| SCHEMBL3372755 | 0.85 | AAK1 (0.46) | AAK1CACNA1BMCL1MMP2MMP9 | |
| SCHEMBL12864435 | 0.83 | MCL1 (0.39) | CACNA1BMCL1ELANEMMP2MMP9 | |
| SCHEMBL14092834 | 0.81 | — | — | |
| SCHEMBL8278952 | 0.80 | MCL1 (0.45) | MCL1BCL2BCL2L1 | |
| SCHEMBL18105019 | 0.80 | MCL1 (0.45) | MCL1BCL2BCL2L1 | |
| SCHEMBL3372052 | 0.79 | ELANE (0.42) | MCL1ELANEMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2027144-B1 | MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS | MSD ITALIA SRL (IT) | 2015-04-29 | — | — | EP | disclosed |
| US-8178520-B2 | Macrocyclic compounds as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-05-15 | — | — | US | disclosed |
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258891-A1 | Macrocyclic Compounds As Antiviral Agents | ZC3HAV1, HAVCR2, ZC3HAV1L | AAK1 4084/4885CACNA1B 4063/4885MCL1 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.